Evidence map›Paper›PMID 36515321›Full record

ReviewJournal of dental research2023

Fibromodulin, a Multifunctional Matricellular Modulator.

Z Zheng, H S Granado, C Li

Open access · greenAbstract readReview
In one paragraph

Review in Journal of dental research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Z ZhengDavid Geffen School of Medicine, University of California, Los Angeles, CA, USA.
H S GranadoDepartment of Orthodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
C LiDepartment of Orthodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · USUniversity of California, Los Angeles · US

Funding

Global Transcriptional Analyses of Fibromodulin Reprogrammed Cells - A New Multipotent Cell Source for Craniofacial Tissue ReconstructionR03DE030236 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHENG, ZHONG · 2021 to 2022
$312k
NIDCR NIH HHS R03 DE030236
6 · The paper itself

Abstract

Fibromodulin (FMOD) is an archetypal member of the class II small leucine-rich proteoglycan family. By directly binding to extracellular matrix structural components, such as collagen and lysyl oxidase, FMOD regulates collagen cross-linking, packing, assembly, and fibril architecture via a multivalent interaction. Meanwhile, as a pluripotent molecule, FMOD acts as a ligand of various cytokines and growth factors, especially those belonging to the transforming growth factor (TGF) β superfamily, by interacting with the corresponding signaling molecules involved in cell adhesion, spreading, proliferation, migration, invasion, differentiation, and metastasis. Consequently, FMOD exhibits promigratory, proangiogenic, anti-inflammatory, and antifibrogenic properties and plays essential roles in cell fate determination and maturation, progenitor cell recruitment, and tissue regeneration. The multifunctional nature of FMOD thus enables it to be a promising therapeutic agent for a broad repertoire of diseases, including but not limited to arthritis, temporomandibular joint disorders, caries, and fibrotic diseases among different organs, as well as to be a regenerative medicine candidate for skin, muscle, and tendon injuries. Moreover, FMOD is also considered a marker for tumor diagnosis and prognosis prediction and a potential target for cancer treatment. Furthermore, FMOD itself is sufficient to reprogram somatic cells into a multipotent state, creating a safe and efficient cell source for various tissue reconstructions and thus opening a new avenue for regenerative medicine. This review focuses on the recent preclinical efforts bringing FMOD research and therapies to the forefront. In addition, a contemporary understanding of the mechanism underlying FMOD's function, particularly its interaction with TGFβ superfamily members, is also discussed at the molecular level to aid the discovery of novel FMOD-based treatments.

Indexed as

CollagenWound HealingCell AdhesionCell DifferentiationExtracellular Matrix ProteinsFibromodulinTransforming Growth Factor betaCollagenExtracellular Matrix ProteinsFibromodulinTransforming Growth Factor betacell fate determinationfibril assemblyfibromodulinmatricellular modulatorsignal transductionsmall leucine-rich proteoglycan

Identifiers

PMID36515321
PMCPMC9986681
OpenAlexW4311492537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.